Swiss pharmaceutical giant Galderma sees an opportunity in what is known as the “Ozempic face” phenomenon. The CEO of the company believes that the popularity of weight-loss drugs like Ozempic could potentially boost its facial fillers business. According to one cosmetic dermatologist, the Ozempic face is a result of aging and rapid weight loss which can lead to a sunken-in look in patients’ faces.
Galderma creates skin care treatments and has products like Sculptra that are designed to counteract the gaunt look associated with the Ozempic face. The company has started a study to evaluate the effects of their products on patients who are using GLP-1 treatments like Ozempic. Enrollment for the study is ongoing and results may be available by the end of the year.
Dr. Joshua Zeichner, a dermatologist, has stated that he sees patients with complaints of the Ozempic face almost daily due to the widespread use of medications like Ozempic. Cosmetic dermatologist Dr. Paul Jarrod Frank, who coined the term, explains that the Ozempic face is a result of aging and rapid weight loss.
Last month, Galderma went public on the SIX Swiss Exchange and reported a surge in shares. The company also reported a 12.4% increase year-over-year in sales, reaching $1 billion in the first quarter. Galderma, which also owns Cetaphil, a popular drug store brand, is capitalizing on the opportunity presented by the Ozempic face phenomenon to boost its facial fillers business.